// App-Quantinova.ai

TPS3107 : ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors.

Researchers

Presenter

  • Jeffrey R. Infante

Principal Investigators

  • Christoph M Ahlers

  • F. Stephen Hodi

  • Sophie Postel-Vinay

  • Jan H. M. Schellens

  • John Heymach

  • Karen A. Autio

  • Mary S. Barnette

  • Herbert Struemper

  • Maura Watmuff

  • Elaine Marie Paul

  • David Ross Kaufman

  • Jeffrey S. Weber

  • Axel Hoos

Medical Centers

  • Sarah Cannon Research Institute, Nashville, TN

  • GlaxoSmithKline, Collegeville, PA

  • Dana-Farber Cancer Institute, Boston, MA

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Parexel, Durham, NC

  • Glaxo Smith Kline, Durham, NC

  • Merck & Co., Inc., Kenilworth, NJ

  • NYU Langone Medical Center, New York, NY

Locations

  • United States

  • France

  • Netherlands

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • Squamous cell carcinoma of the head and neck

  • Triple-negative breast cancer

  • Non Small Cell Lung cancer

  • Squamous cell carcinoma

  • Small cell lung cancer

  • Solid malignancies

  • Colorectal Cancer

  • Renal cell carcinoma

  • Soft tissue sarcoma

  • Breast cancer

  • Lung Cancer

  • Melanoma

  • Sarcoma

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Multicenteric

  • Cohort

  • First-In-Human

Phase

  • I

Study Id's

  • NCT02528357

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved